WO2004071377A3 - Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a) - Google Patents

Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a) Download PDF

Info

Publication number
WO2004071377A3
WO2004071377A3 PCT/EP2004/001054 EP2004001054W WO2004071377A3 WO 2004071377 A3 WO2004071377 A3 WO 2004071377A3 EP 2004001054 W EP2004001054 W EP 2004001054W WO 2004071377 A3 WO2004071377 A3 WO 2004071377A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde3a
diseases
phosphodiesterase
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2004/001054
Other languages
French (fr)
Other versions
WO2004071377A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2004071377A2 publication Critical patent/WO2004071377A2/en
Publication of WO2004071377A3 publication Critical patent/WO2004071377A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a human PDE3A which is associated with the cardiovascular diseases, hematological diseases, cancer and gastrointestinal diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, cancer and gastrointestinal diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE3A as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/001054 2003-02-17 2004-02-05 Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a) WO2004071377A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003539.8 2003-02-17
EP03003539 2003-02-17

Publications (2)

Publication Number Publication Date
WO2004071377A2 WO2004071377A2 (en) 2004-08-26
WO2004071377A3 true WO2004071377A3 (en) 2004-11-11

Family

ID=32864943

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001054 WO2004071377A2 (en) 2003-02-17 2004-02-05 Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a)

Country Status (1)

Country Link
WO (1) WO2004071377A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181631A1 (en) * 2014-05-30 2015-12-03 Oslo Universitetssykehus Hf Serca2-pde3a interaction peptides and uses thereof
WO2018006014A1 (en) * 2016-07-01 2018-01-04 Emerging Viral Diagnostics (Hk) Limited Compositions and methods for providing a prognosis for influenza infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1085092A1 (en) * 1999-09-17 2001-03-21 Pfizer Limited Phosphodiesterase enzymes
WO2002070469A2 (en) * 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
WO2003012030A2 (en) * 2001-08-01 2003-02-13 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1085092A1 (en) * 1999-09-17 2001-03-21 Pfizer Limited Phosphodiesterase enzymes
WO2002070469A2 (en) * 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
WO2003012030A2 (en) * 2001-08-01 2003-02-13 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOI YOUNG-HUN ET AL: "Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes", BIOCHEMICAL JOURNAL, vol. 353, no. 1, January 2001 (2001-01-01), pages 41 - 50, XP002285579, ISSN: 0264-6021 *
NAGAOKA TADASU ET AL: "Cyclic nucleotide phosphodiesterase 3 expression in vivo: Evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats", DIABETES, vol. 47, no. 7, July 1998 (1998-07-01), pages 1135 - 1144, XP002285576, ISSN: 0012-1797 *
WAGNER R S ET AL: "Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 282, no. 3, 1997, pages 1650 - 1657, XP002285577, ISSN: 0022-3565 *
WECHSLER JEREMY ET AL: "Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 41, 11 October 2002 (2002-10-11), pages 38072 - 38078, XP002285578, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004071377A2 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
EP2017620A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2004071377A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2004044229A3 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2)
WO2005026724A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a5 (slc22a5)
WO2005040791A3 (en) Diagnostics and therapeutics for diseases associated with somatostatin- and angiogenin-like peptide receptor (salpr)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2004075812A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 3b (pde3b)
WO2004097422A3 (en) Diagnostics and therapeutics for diseases associated with calcitonin receptor (calcr)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2004080270A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1b (pde1b)
WO2005114209A3 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 2 (grk2)
WO2006013015A3 (en) Diagnostics and therapeutics for diseases associated with marapsin (mpn)
WO2005026737A3 (en) Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4)
WO2005052574A3 (en) Diagnostics and therapeutics for diseases associated with potassium channel subfamily k, member 4 (kcnk4)
WO2004071379A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y10 (p2y10)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase